{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:35:33Z","timestamp":1791246933983,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Struct Biol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib, nilotinib, and dasatinib, and obtained IC<jats:sub>50<\/jats:sub>values of 80 nM, 380 nM, and &gt;100 \u03bcM, respectively. Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation of the protein environment around the flavin prosthetic group in NQO2. We have determined the crystal structure of the complex of imatinib with human NQO2 at 1.75 \u00c5 resolution, which reveals that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring. We find that phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate other aspects of NQO2 function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site. The overall conformation of imatinib when bound to NQO2 resembles the folded conformation observed in some kinase complexes. Interactions made by imatinib with residues at the rim of the active site provide an explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib. These interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1 by these compounds. Taken together, these studies provide insight into the mechanism of NQO2 inhibition by imatinib, with potential implications for drug design and treatment of chronic myelogenous leukemia in patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1472-6807-9-7","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T07:25:01Z","timestamp":1235460301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)"],"prefix":"10.1186","volume":"9","author":[{"given":"Jonathan A","family":"Winger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hantschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,24]]},"reference":[{"issue":"17","key":"227_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999, 340(17):1330\u20131340.","journal-title":"N Engl J Med"},{"issue":"4946","key":"227_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247(4946):1079\u20131082.","journal-title":"Science"},{"issue":"Suppl 2","key":"227_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/10428199309064268","volume":"11","author":"CL Sawyers","year":"1993","unstructured":"Sawyers CL: Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leukemia Lymphoma 1993, 11(Suppl 2):101\u2013103.","journal-title":"Leukemia Lymphoma"},{"issue":"7","key":"227_CR4","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7):2640\u20132653.","journal-title":"Blood"},{"issue":"4","key":"227_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G: Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia Lymphoma 2008, 49(4):615\u2013619.","journal-title":"Leukemia Lymphoma"},{"issue":"15","key":"227_CR6","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62(15):4236\u20134243.","journal-title":"Cancer Res"},{"issue":"6","key":"227_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003, 112(6):859\u2013871.","journal-title":"Cell"},{"issue":"5486","key":"227_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289(5486):1938\u20131942.","journal-title":"Science"},{"issue":"1","key":"227_CR9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295(1):139\u2013145.","journal-title":"J Pharmacol Exp Ther"},{"issue":"30","key":"227_CR10","doi-asserted-by":"publisher","first-page":"31655","DOI":"10.1074\/jbc.M403319200","volume":"279","author":"CD Mol","year":"2004","unstructured":"Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004, 279(30):31655\u201331663.","journal-title":"J Biol Chem"},{"issue":"7","key":"227_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347(7):481\u2013487.","journal-title":"N Engl J Med"},{"issue":"7","key":"227_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472\u2013480.","journal-title":"N Engl J Med"},{"issue":"14","key":"227_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(14):1038\u20131042.","journal-title":"N Engl J Med"},{"issue":"14","key":"227_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031\u20131037.","journal-title":"N Engl J Med"},{"issue":"23","key":"227_CR15","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408\u20132417.","journal-title":"N Engl J Med"},{"issue":"5531","key":"227_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876\u2013880.","journal-title":"Science"},{"issue":"2","key":"227_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117\u2013125.","journal-title":"Cancer Cell"},{"issue":"2","key":"227_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2):129\u2013141.","journal-title":"Cancer Cell"},{"issue":"24","key":"227_CR19","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354(24):2542\u20132551.","journal-title":"N Engl J Med"},{"issue":"27","key":"227_CR20","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47(27):6658\u20136661.","journal-title":"J Med Chem"},{"issue":"12","key":"227_CR21","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110(12):4055\u20134063.","journal-title":"Blood"},{"issue":"9","key":"227_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, et al.: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25(9):1035\u20131044.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"227_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bcp.2006.04.029","volume":"72","author":"CM Celli","year":"2006","unstructured":"Celli CM, Tran N, Knox R, Jaiswal AK: NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006, 72(3):366.","journal-title":"Biochem Pharmacol"},{"key":"227_CR24","first-page":"85","volume-title":"Vitam Horm","author":"X Gong","year":"2008","unstructured":"Gong X, Gutala R, Jaiswal AK: Quinone Oxidoreductases and Vitamin K Metabolism. In Vitam Horm. Volume 78. Edited by: Litwack G. Academic Press; 2008:85\u2013101."},{"issue":"1\u20132","key":"227_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2005.09.019","volume":"71","author":"F Vella","year":"2005","unstructured":"Vella F, Ferry G, Delagrange P, Boutin JA: NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005, 71(1\u20132):1\u201312.","journal-title":"Biochem Pharmacol"},{"issue":"36","key":"227_CR26","doi-asserted-by":"publisher","first-page":"11417","DOI":"10.1021\/bi049162o","volume":"43","author":"L Buryanovskyy","year":"2004","unstructured":"Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43(36):11417\u201311426.","journal-title":"Biochemistry"},{"issue":"2","key":"227_CR27","first-page":"625","volume":"9","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, et al.: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9(2):625\u2013632.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"227_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/abbi.1997.0344","volume":"347","author":"K Wu","year":"1997","unstructured":"Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, Chen S: Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997, 347(2):221\u2013228.","journal-title":"Arch Biochem Biophys"},{"key":"227_CR29","first-page":"83","volume-title":"Comprehensive biological catalysis: a mechanistic reference","author":"BA Palfey","year":"1998","unstructured":"Palfey BA, Massey V: Flavin-Dependent Enzymes. In Comprehensive biological catalysis: a mechanistic reference. Volume 3. Edited by: Sinnott M. San Diego: Academic Press; 1998:83\u2013154."},{"issue":"3","key":"227_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1042\/bj0540437","volume":"54","author":"LG Whitby","year":"1953","unstructured":"Whitby LG: A new method for preparing flavin-adenine dinucleotide. Biochem J 1953, 54(3):437\u2013442.","journal-title":"Biochem J"},{"issue":"31","key":"227_CR31","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.1021\/bi990799v","volume":"38","author":"CE Foster","year":"1999","unstructured":"Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM: Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999, 38(31):9881\u20139886.","journal-title":"Biochemistry"},{"issue":"6359","key":"227_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/355472a0","volume":"355","author":"AT Brunger","year":"1992","unstructured":"Brunger AT: Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355(6359):472\u2013475.","journal-title":"Nature"},{"issue":"5","key":"227_CR33","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1073\/pnas.94.5.1669","volume":"94","author":"Q Zhao","year":"1997","unstructured":"Zhao Q, Yang XL, Holtzclaw WD, Talalay P: Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). P Natl Acad Sci U S A 1997, 94(5):1669\u20131674.","journal-title":"P Natl Acad Sci U S A"},{"issue":"24","key":"227_CR34","doi-asserted-by":"publisher","first-page":"7714","DOI":"10.1021\/jm050730n","volume":"48","author":"M AbuKhader","year":"2005","unstructured":"AbuKhader M, Heap J, De Matteis C, Kellam B, Doughty SW, Minton N, Paoli M: Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. J Med Chem 2005, 48(24):7714\u20137719.","journal-title":"J Med Chem"},{"issue":"1","key":"227_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/BJ20071373","volume":"413","author":"B Calamini","year":"2008","unstructured":"Calamini B, Santarsiero BD, Boutin JA, Mesecar AD: Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008, 413(1):81\u201391.","journal-title":"Biochem J"},{"issue":"1","key":"227_CR36","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.bbrc.2005.08.081","volume":"336","author":"Y Fu","year":"2005","unstructured":"Fu Y, Buryanovskyy L, Zhang Z: Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem Biophys Res Commun 2005, 336(1):332\u2013338.","journal-title":"Biochem Biophys Res Commun"},{"issue":"35","key":"227_CR37","doi-asserted-by":"publisher","first-page":"23829","DOI":"10.1074\/jbc.M801371200","volume":"283","author":"Y Fu","year":"2008","unstructured":"Fu Y, Buryanovskyy L, Zhang Z: Quinone reductase 2 is a catechol quinone reductase. J Biol Chem 2008, 283(35):23829\u201323835.","journal-title":"J Biol Chem"},{"issue":"7","key":"227_CR38","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1073\/pnas.97.7.3177","volume":"97","author":"M Faig","year":"2000","unstructured":"Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, Amzel LM: Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A 2000, 97(7):3177\u20133182.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"227_CR39","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/S0021-9258(18)60260-1","volume":"237","author":"S Liao","year":"1962","unstructured":"Liao S, Dulaney JT, Williams-Ashman HG: Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide. J Biol Chem 1962, 237(9):2981\u20132987.","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"227_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1107\/S0907444906047287","volume":"63","author":"SW Cowan-Jacob","year":"2007","unstructured":"Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW: Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D 2007, 63(Pt 1):80\u201393.","journal-title":"Acta Crystallogr D"},{"issue":"4","key":"227_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/prot.21633","volume":"70","author":"M Jacobs","year":"2008","unstructured":"Jacobs M, Caron P, Hare B: Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck\/imatinib complex. Proteins 2008, 70(4):1451\u20131460.","journal-title":"Proteins"},{"issue":"3","key":"227_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.str.2007.01.015","volume":"15","author":"MA Seeliger","year":"2007","unstructured":"Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J: c-Src binds to the cancer drug imatinib with an inactive Abl\/c-Kit conformation and a distributed thermodynamic penalty. Structure 2007, 15(3):299\u2013311.","journal-title":"Structure"},{"issue":"2","key":"227_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2):129\u2013141.","journal-title":"Cancer Cell"},{"issue":"53","key":"227_CR44","doi-asserted-by":"publisher","first-page":"55827","DOI":"10.1074\/jbc.M409792200","volume":"279","author":"S Atwell","year":"2004","unstructured":"Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, et al.: A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004, 279(53):55827\u201355832.","journal-title":"J Biol Chem"},{"issue":"6","key":"227_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.str.2005.03.012","volume":"13","author":"SW Cowan-Jacob","year":"2005","unstructured":"Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T: The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005, 13(6):861\u2013871.","journal-title":"Structure"},{"issue":"48","key":"227_CR46","doi-asserted-by":"publisher","first-page":"46131","DOI":"10.1074\/jbc.M208675200","volume":"277","author":"DJ Long 2nd","year":"2002","unstructured":"Long DJ 2nd, Iskander K, Gaikwad A, Arin M, Roop DR, Knox R, Barrios R, Jaiswal AK: Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002, 277(48):46131\u201346139.","journal-title":"J Biol Chem"},{"issue":"17","key":"227_CR47","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-04-0763","volume":"64","author":"K Iskander","year":"2004","unstructured":"Iskander K, Paquet M, Brayton C, Jaiswal AK: Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004, 64(17):5925\u20135928.","journal-title":"Cancer Res"},{"issue":"1","key":"227_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/sj.leu.2404025","volume":"20","author":"PR Pilot","year":"2006","unstructured":"Pilot PR, Sablinska K, Owen S, Hatfield A: Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006, 20(1):148. author reply 149","journal-title":"Leukemia"},{"issue":"3","key":"227_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","volume":"111","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, et al.: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008, 111(3):1039\u20131043.","journal-title":"Blood"},{"key":"227_CR50","volume-title":"Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography","author":"AGW Leslie","year":"1992","unstructured":"Leslie AGW: Recent changes to the MOSFLM package for processing film and image plate data. In Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography. Volume 26. Warrington LD, UK; 1992."},{"key":"227_CR51","doi-asserted-by":"crossref","unstructured":"The CCP4 suite: programs for protein crystallography Acta Crystallogr D 1994, 50(Pt 5):760\u2013763.","DOI":"10.1107\/S0907444994003112"},{"key":"227_CR52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1107\/S0907444905001617","volume":"61","author":"AJ McCoy","year":"2005","unstructured":"McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ: Likelihood-enhanced fast translation functions. Acta Crystallogr D 2005, 61: 458\u2013464.","journal-title":"Acta Crystallogr D"},{"issue":"5","key":"227_CR53","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/8263","volume":"6","author":"A Perrakis","year":"1999","unstructured":"Perrakis A, Morris R, Lamzin VS: Automated protein model building combined with iterative structure refinement. Nat Struct Biol 1999, 6(5):458\u2013463.","journal-title":"Nat Struct Biol"},{"key":"227_CR54","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D 2004, 60: 2126\u20132132.","journal-title":"Acta Crystallogr D"},{"key":"227_CR55","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1107\/S0907444902016657","volume":"58","author":"PD Adams","year":"2002","unstructured":"Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC: PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D 2002, 58: 1948\u20131954.","journal-title":"Acta Crystallogr D"},{"key":"227_CR56","first-page":"W375","volume-title":"Nucleic Acids Res","author":"IW Davis","year":"2007","unstructured":"Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, et al.: MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, (35 Web Server):W375\u2013383."},{"key":"227_CR57","unstructured":"The PyMOL Molecular Graphics System[http:\/\/pymol.sourceforge.net\/]"}],"container-title":["BMC Structural Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6807-9-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T21:32:52Z","timestamp":1738963972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcstructbiol.biomedcentral.com\/articles\/10.1186\/1472-6807-9-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,24]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1186\/1472-6807-9-7","relation":{},"ISSN":["1472-6807"],"issn-type":[{"value":"1472-6807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,24]]},"assertion":[{"value":"8 January 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}